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Findings from the Psychiatric Genomics Consortium
genome-wide association study (GWAS) showed that variation at the DRD2 locus is associated with schizophrenia
risk. However, the functional significance of rs2514218, the
top DRD2 single nucleotide polymorphism in the GWAS,
is unknown. Dopamine D2 receptor binding is a common
mechanism of action for all antipsychotic drugs, and DRD2
variants were related to antipsychotic response in previous
studies. The present study examined whether rs2514218
genotype could predict antipsychotic response, including
efficacy and adverse events, in a cohort of patients with
first episode of psychosis treated with either risperidone or
aripiprazole for 12 weeks. Subjects were genotyped using
the Illumina Infinium HumanOmniExpressExome array
platform. After standard quality control, data from 100
subjects (49 randomly assigned to treatment with aripiprazole and 51 assigned to risperidone) was available for analysis. Subjects were assessed for psychotic symptomatology
and medication-related adverse events weekly for 4 weeks,
then biweekly for 8 weeks. Linear mixed model analysis
revealed that the homozygotes for the risk (C) allele at
rs2514218 had significantly greater reduction in positive
symptoms during 12 weeks of treatment compared to the
T allele carriers. In the aripiprazole group, C/C homozygotes also reported more akathisia than the T allele carriers, while in the risperidone group, male T allele carriers
demonstrated greater prolactin elevations compared to
male C/C homozygotes. These findings suggest that the
schizophrenia risk variant at the DRD2 locus (or another
variant in close proximity) is associated with observable
differences in response to treatments which reduce striatal
dopamine signaling.
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Introduction
The recent large-scale genome-wide association study
(GWAS) from the Psychiatric Genomics Consortium
(PGC) represents a watershed moment in schizophrenia research, revealing 108 genomic loci that are reliably
associated with schizophrenia risk.1 At the same time, the
PGC results raised as many questions as answers, insofar
as the functional significance of the risk-associated variants remains largely uncharacterized. One of the loci that
may be particularly relevant to schizophrenia treatment
is DRD2,2 the gene coding for the dopamine D2 receptor, which is a binding target of all available antipsychotic drugs.3 The top single nucleotide polymorphism
(SNP) reported by the PGC at this locus is rs2514218,
about 47 kb upstream from DRD2; this SNP has not been
examined in any pharmacogenetics study to date.
While antipsychotic medications are the primary intervention for schizophrenia and related psychotic disorders,4 many patients frequently discontinue or switch drug
regimens due to lack of efficacy and/or treatment-emergent side effects.5 There is currently a lack of clinically relevant, biologically validated predictors of antipsychotic
treatment response, so that clinicians often rely on past
medication history to determine which antipsychotic to
use. However, no such information is available for patients
with first-episode psychosis. Pharmacogenetics research
focuses on the identification of genetic variants that
predict who may optimally benefit from specific drugs6
and can provide a prognostic biomarker that is readily
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obtainable for any patient regardless of clinical status or
history.
Previous research has found that variants in DRD2
may be predictive of antipsychotic drug response.7,8
Therefore, we examined whether rs2514218 was associated with antipsychotic drug response in a cohort of
patients with first-episode psychosis. While symptomatology in psychotic disorders is multifaceted (involving
positive, negative, and cognitive symptoms), D2 receptor activity of antipsychotic medications is specifically
associated with reduction of positive symptoms such as
hallucinations and delusions9 but is much less effective
in reducing negative symptoms and largely ineffective
for cognitive symptoms (see this issue).10 Moreover, a
higher degree of D2 blockade is associated with greater
risk of specific drug-induced adverse events such as
extrapyramidal symptoms (EPS) and akathisia,11 and
D2 antagonism in the tuberoinfundibular pathway is
thought to underlie prolactin elevation in response to
first-generation agents, as well as risperidone (but not
aripiprazole).12 Consequently, we aimed to test a primary
hypothesis that DRD2 variants will affect change in positive symptoms and secondary hypotheses that the same
variant will also be associated with EPS and akathisia,
as well as risperidone-induced prolactin elevation. By
contrast, we hypothesized that the DRD2 variant would
not be associated with change in general psychopathology, global functioning, or negative symptoms.
Methods
Participants
Study subjects were a subset of participants in a randomized, multisite, double-blind, clinical trial for
patients with first-episode psychosis (this issue),13 including DSM-IV diagnoses of schizophrenia, schizoaffective
disorder, schizophreniform disorder, and psychotic disorder Not Otherwise Specified (NOS). The sample of the
clinical trial consisted of 198 subjects, but only a subset
participated in the genetic study, which was added subsequent to the enrollment of the first 49 subjects, and
was not available at some study sites. The present study
had genetic data on 100 patients (75 men and 25 women;
mean age = 21.5 years, SD = 5.1, range = 15–39) who
provided written informed consent (or assent in the case
of minors, with written consent from parent/guardian)
for both the trial and genetic analyses. About 24% of
subjects (n = 24) were antipsychotic naive; none had
more than 2 weeks of lifetime antipsychotic exposure.
Subjects were from 6 different sites in the greater New
York city area and at sites in San Antonio, TX and
Calgary, Alberta, Canada. All study procedures were
approved by Institutional Review Boards (IRBs) at each
of the participating sites, with the Feinstein Institute for
Medical Research IRB as the coordinating center for the
clinical trial and genetics studies.

Treatment
Participants were stratified by site, previous antipsychotic
exposure (none vs any), and diagnosis (psychotic disorder NOS vs other eligible diagnoses) and were randomly
assigned on a 1 to 1 basis to double-masked treatment with
either aripiprazole (5–30 mg/d) or risperidone (1–6 mg/d)
for 12 weeks. Study medication was packaged in identically appearing capsules at 3 different dosing levels (level
1: 5 mg of aripiprazole or 1 mg of risperidone; level 2:
10 mg of aripiprazole or 2 mg of risperidone; and level 3:
15 mg of aripiprazole or 3 mg of risperidone). The study
allowed for prescription of up to 2 study capsules per
day providing a total of 6 possible levels of milligrams of
daily study medication. The initial daily dose was 1 study
capsule (ie, 5 mg of aripiprazole or 1 mg of risperidone).
Medication doses were advanced according to a titration
schedule until response criteria were achieved or doselimiting side effects occurred. Study psychiatrists had
the option of advancing or slowing the titration schedule
for clinical needs (eg, side effect management). Limited
concomitant medications were permitted to manage side
effects: benztropine for EPS; lorazepam or propranolol
for akathisia; and lorazepam for agitation or anxiety. As
presented in (this issue),13 there was no significant difference in treatment response rate between the 2 treatment
arms for the full study cohort (n = 198).
Assessment
Raters blind to treatment condition and DRD2 genotype conducted weekly assessments during the first 4
weeks, then biweekly assessments for the subsequent 8
weeks of the trial. Psychopathology was assessed using
the Brief Psychiatric Rating Scale (BPRS),14 Schedule
for Assessment of Negative Symptoms (SANS),15 and
Clinical Global Impression Scale (CGI-severity).16 As
described in the primary trial report (this issue),13 4 of
the BPRS items were used to compute the total positive symptoms score: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought
content. Four global ratings from the SANS were used
to represent negative symptoms: affective flattening,
alogia, avolition-apathy, and asociality-anhedonia.
Interrater reliability, as measured by intraclass correlation coefficients (ICCs), were high for all 4 BPRS items:
for conceptual disorganization, ICC = 0.94 (95% CI:
0.76, 0.99); for grandiosity, ICC = 0.92 (95% CI: 0.80,
0.98); for hallucinatory behavior, ICC = 0.93 (0.76,
0.99); and for unusual thought content, ICC = 0.92
(95% CI: 0.82, 0.98) and for the SANS global items
affective flattening 0.75 (95% CI: 0.43, 0.93), alogia
0.66 (95% CI: 0.36, 0.89), avolition-apathy 0.69 (95%
CI: 0.38, 0.91), and asociality-anhedonia 0.52 (95%
CI: 0.17, 0.85). Patients’ diagnoses were confirmed
with a Structured Clinical Interview of Axis I DSM-IV
Disorders (SCID).
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Drug-induced adverse events were measured by
Simpson-Angus Scale for EPS17 and Barnes Akathisia
Scale (BAS).18 An overall EPS severity score was calculated as the sum of the following Simpson-Angus
EPS Scale items: gait, rigidity of major joints, tremor,
akinesia, and akathisia. Akathisia was measured by the
global item of the BAS. Blood draw was performed at
baseline, week 4, week 8, and week 12 to measure prolactin levels.

difference was not statistically significant (χ2 = 8.89,
df = 4, P = .064). To control for the presence of different continental ancestry groups in our cohort, and the
consequent risk of population stratification, principal
component analysis was conducted in the full Illumina
dataset. Following the convention for genomic analysis,
the first 5 principal components were used as covariates
in subsequent analysis. Genetic analysis was conducted
in Golden Helix’s SNP and Variation Suite version 8.3.4
(Golden Helix, Inc.).

Genotyping
Peripheral venous blood was drawn for subjects who
consented to the genetic study. DNA was extracted from
lymphocytes and genotyping was performed using the
Illumina Infinium HumanOmniExpressExome array
platform. After standard quality control, data from
100 subjects were used in subsequent analysis. For
rs2514218, the C allele is the schizophrenia risk allele
with a frequency of 81% worldwide.1 Due to the fact
that there were only 13 homozygotes for the T allele,
patients were dichotomized for primary analyses as
homozygous for the common (risk) allele or as carriers of the minor allele (n = 56 for C/C and n = 44 for
T allele carriers). Genotype groups (C/C vs T carriers) did not significantly differ on sex, diagnosis, and
medication assignment (all P values > .20, see table 1).
There were slightly more African American subjects
in the C/C homozygotes than in the T carriers, but the

Statistical Analysis
Because missing data is inherent in any clinical trial
and may be dependent on the observed outcomes, a
mixed-model approach to longitudinal data analysis
was used (SPSS Mixed Linear Models, IBM), with time
as the primary within-subject variable and genotype as
the primary between-subject variable. A random intercept in the mixed model was used to account for correlation of measurements over time among subjects with
an unstructured covariance matrix. The difference in
slopes of the outcomes between the 2 genotype groups
was assessed using group-by-time interaction term in the
mixed model.
The primary outcome was BPRS positive symptoms.
Secondary outcome variables were EPS, akathisia, and
prolactin levels. Tertiary outcomes were BPRS total
scores, CGI-severity scores, and 4 negative symptoms.

Table 1. Demographic and Clinical Data in 2 Genotype Groups of rs2514218

Male sex, n (%)
Age (y), mean ± SD
Medication (aripiprazole), n (%)
Race, n (%)
Asian
African American
Hispanic
Caucasian
Others
Schizophrenia diagnosis, n (%)
BPRS total scores, mean ± SD
Duration of untreated psychosis
(wk), mean ± SD
Medication dose (level)a
Treatment responderb, n (%)
Comedications
Benzodiazepine use, %
Anticholinergics use, %
Beta-blocker use, %

C/C Homozygotes (n = 56)

T Carriers (n = 44)

P Values

41 (73.2)
21.4 ± 5.1
29 (51.8)

34 (77.3)
21.8 ± 5.0
20 (45.5)

2 (3.6)
30 (53.6)
6 (10.7)
15 (26.8)
3 (5.4)
38 (67.8)
45.4 ± 7.4
128.8 ± 221.8

3 (6.8)
11 (25.0)
8 (18.2)
20 (45.5)
2 (4.5)
26 (59.1)
44.0 ± 8.7
90.7 ± 110.7

.64
.69
.53
.06

3.3 ± 1.4
32 (57.1)

2.9 ± 1.2
21 (47.7)

.12
.35

44.6
21.4
8.9

56.8
25.0
13.6

.23
.67
.46

.41
.37
.30

Note: BPRS, Brief Psychiatric Rating Scale.
For medication dose, levels 1–6 represented 1, 2, 3, 4, 5, and 6 mg/d for risperidone and 5, 10, 15, 20, 25, and 30 mg/d for aripiprazole,
respectively.
b
Treatment response: response criteria required (1) a rating of 3 (“mild”) or less on all of the following items of the BPRS: conceptual
disorganization, grandiosity, hallucinatory behavior, and unusual thought content and (2) a Clinical Global Impression ScaleImprovement rating of much or very much improved on 2 consecutive rating assessments (this issue).13
a

1250

DRD2 Variant and Antipsychotic Response

Each outcome variable was analyzed separately, while
controlling for sex, age, medication assignment, and
genomic principal components, using maximum likelihood estimation. Due to differential effects of drugs on
EPS, akathisia, and prolactin (see this issue),13 analyses
of these variables were conducted in the aripiprazole and
risperidone subgroups separately. Final models included
genotype group as a fixed factor, time, any significant
covariates, and a genotype group-by-time interaction
term (if statistically significant).
Results
Table 1 shows descriptive statistics for the 2 genotype groups. There was no significant difference in age,
sex, medication assignment, ethnicity, diagnosis, baseline BPRS total score, treatment response, duration
of untreated psychosis, medication modal dose, and
comedication use.
Positive Symptoms
The mixed-model analysis showed that the C/C homozygotes had a greater reduction in positive symptoms
during 12 weeks of treatment, compared to the T carriers. For the genotype × time interaction, F(1,111) = 4.13,
P = .044, Cohen’s f2 = 0.036 (effect size measure, equivalent to Cohen’s d = 0.38).19 Unsurprisingly, the main
effect of time was also strongly significant in that both
genotype groups had large reductions in positive symptoms over 12 weeks, F(1,111) = 178.33, P < .001 . None
of the covariates affected the results. Table 2 presents the
least square estimates of means and SDs of the outcome
variable at each time point, separately for the 2 genotype
groups. While none of the single-time point comparisons
between the 2 groups in table 2 were statistically significant, the significant interaction term demonstrates that
the slopes differed over time. Specifically, the C/C homozygotes were higher in positive symptoms at baseline, but
they improved more by week 12. For illustrative purposes,
Table 2. BPRS Positive Symptoms Scores at Each Follow-up
(Least Square Estimate, mean ± SE, unadjusted)

Week 0
Week 1
Week 2
Week 3
Week 4
Week 6
Week 8
Week 10
Week 12

CC Homozygotes

n

T Carriers

n

P Value

14.80 ± 0.46
11.05 ± 0.47
9.59 ± 0.48
9.52 ± 0.48
8.51 ± 0.48
7.84 ± 0.50
6.75 ± 0.49
6.76 ± 0.51
6.51 ± 0.52

56
53
49
49
49
44
44
40
38

13.91 ± 0.52
11.16 ± 0.54
9.54 ± 0.55
8.72 ± 0.56
9.26 ± 0.56
8.41 ± 0.56
7.75 ± 0.57
7.42 ± 0.60
7.64 ± 0.57

44
39
37
35
34
34
32
27
33

.198
.869
.950
.273
.310
.447
.189
.404
.143

Note: Numbers in the “n” columns are the actual sample size for
observed cases at each time point.

and to represent the data in a clinically meaningful way,
we calculated the percent reduction from baseline at each
time point. As shown in figure 1, the longitudinal trajectories of the 2 genotype groups separated after week
4, with the curve for the C/C homozygotes being more
steep. Using the least square estimates of the percent
reduction at each time point in the mixed model, the 2
genotype groups were significantly different at weeks 4, 6,
and 12 (P’s = .039, .049, and .030, respectively). Because
only 1 subject dropped out between week 3 and 4, it was
unlikely that differential drop-out rates might explain
the separation of the 2 curves. At the end of 12 weeks,
the C/C group had, on average, 10% greater reduction in
positive symptoms than the T carriers.
EPS, Akathisia, and Prolactin Levels
For the BAS global rating of akathisia, mixed-model
analysis was conducted in the 2 treatment arms separately, because the full trial results revealed that patients
on aripiprazole developed significantly worse akathisia compared to those on risperidone (this issue).13 The
genotype × time interaction was not significant in either
medication arm, nor was the main effect of time, P’s >
.10, which is consistent with the finding in the whole sample (as shown in figure 3, Robinson et al., this issue).13
After removing the nonsignificant interaction term, the
main effect of genotype was statistically significant in
the aripiprazole group (F(1,46) = 4.19, P = .046, Cohen’s
f2 = 0.014, equivalent to Cohen’s d = 0.24). As shown in
figure 2, the C/C homozygotes had worse akathisia than
the T carriers, with estimated mean scores of 0.72 ± 0.11
vs 0.34 ± 0.14 (SE). The main effect of genotype was not
significant in the risperidone group, P > .05.
For EPS total scores, neither the genotype × time interaction nor the main effect of genotype was statistically
significant in either aripiprazole or risperidone groups
(P’s > .10).
Prolactin elevation was a common side effect of risperidone treatment, but aripiprazole is not usually associated
with prolactin elevation. Therefore, mixed-model analysis
was conducted in risperidone group only. Because prolactin is a reproductive hormone and sex plays an important
role, the mixed-model analysis was conducted in males
and females separately. In the risperidone arm, the genotype × time interaction was significant, F(3,68) = 2.80,
P = .046, Cohen’s f2 = 0.019 (equivalent to Cohen’s
d = 0.28), in male subjects (n = 36). The C/C homozygotes (n = 19) had lower elevation of prolactin at week 8
and week 12, compared to T carriers (n = 17) (figure 3).
However, neither interaction nor main effect was significant in females.
BPRS Total Score, CGI, and Negative Symptoms
Mixed-model analysis was conducted for each of these
outcome variables. As expected, none of models produced
1251
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Fig. 1. Percentage of positive symptoms reduction from baseline throughout the 12-week clinical trial, stratified by rs2514218 genotype.
N = 100. Error bars are SEs of the mean. The genotype × week interaction was significant in the mixed-models analysis, F(1,111) = 4.13,
P = .044. BPRS, Brief Psychiatric Rating Scale.

Fig. 2. Mean akathisia scores at baseline and each follow-up visit, stratified by rs2514218 genotype. N = 49. Error bars are SEs of the mean.
The main effect of genotype was significant in the mixed-models analysis, F(1,46) = 4.19, P = .046.

significant genotype × time interaction or genotype main
effects. P values for the interaction terms for BPRS total
score, CGI-severity, affective flattening, alogia, avolitionapathy, and asociality-anhedonia were .133, .070, .305,
.436, .262, and .193, respectively.
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Discussion
To our knowledge, no prior study has identified any
functional effect of genotype at rs2514218, one of the
108 top hits reported from the PGC GWAS. Within the
PGC study, biological assays in blood and postmortem
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Fig. 3. Mean prolactin levels at baseline and each follow-up visit, stratified by rs2514218 genotype. N = 36. Error bars are SEs of the mean.
The genotype × week interaction was significant in the mixed-models analysis, F(3,68) = 2.80, P = .046.

brain tissue identified no detectable relationship between
rs2514218 and DRD2 gene expression levels.1 In the present study, we found that the C/C homozygotes improved
in positive symptoms more than the T carriers during
12 weeks of treatment. Intriguingly, the C allele is both
the schizophrenia risk allele in the PGC GWAS1 and the
common allele in the general population. Speculatively,
while carriage of the minor T allele may be protective for
development of schizophrenia, T carriers who do develop
psychotic disorders may be somewhat more likely to have
a nonstandard pathophysiology with respect to dopamine
signaling. A distinction between 2 subtypes of schizophrenia based on dopamine physiology has been recently
proposed.20 Such a dichotomy is also consistent with our
own data demonstrating that psychotic patients can be
divided into 2 groups based on resting-state functional
magnetic resonance imaging patterns of connectivity
linking the D2-rich striatum with cortex.21 Patients with
psychotic disorders (both first episode and multiepisode)
demonstrating the atypical striatal connectivity pattern
were replicably less likely to meet criteria for symptomatic response following treatment with antipsychotic
medications.
In addition, the C/C homozygotes developed more
akathisia during treatment with aripiprazole compared to
carriers of the T allele. Only a few prior studies have examined the pharmacogenetics of akathisia as a side effect of
antipsychotic medications,22 and none have examined it
in the context of aripiprazole treatment, which has been
associated with greater liability for akathisia in some
studies,23 including our own report (Robinson et al) in this

volume. Further studies are needed to replicate and validate this novel finding. In contrast, there was no significant
association between the SNP and EPS in either aripiprazole or risperidone groups. Furthermore, rs2514218 was
associated with prolactin elevation in males treated with
risperidone, in that C/C homozygotes had lower elevation
of prolactin compared to the T carriers. This effect seems
to be the opposite of what was observed for akathisia
and positive symptoms, in which C/C homozygotes were
more sensitive to medication effects, as described above.
Risperidone is known to cause prolactin elevation and is
hypothesized to act by the dopamine tuberoinfundibular
pathway.24 It has been theorized that antipsychotic drugs
reduce positive symptoms via the mesolimbic pathway
and cause EPS and perhaps akathisia via the nigrostriatal
pathway.24 Perhaps the effect of the DRD2 risk variant is
different across these disparate dopamine pathways, but
this needs further research to elucidate. Our side effect
findings should be interpreted with caution, because the
sample sizes were small for the subgroup analyses. In
addition, many patients were prescribed beta-blockers to
treat akathisia and received anticholinergics to treat EPS.
Although there was no significant difference in comedication use between the 2 genotype groups, the effects of
genotypes on akathisia and EPS could have been masked
or distorted by administration of these comedications.
Several variants in DRD2 have been found to affect
antipsychotic drug response including efficacy and side
effects.6,8,25 It is not surprising because dopamine D2
receptor antagonism is a common mechanism of antipsychotic drug action26 and may be “necessary and sufficient”
1253
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for antipsychotic efficacy.27 Positive symptoms of schizophrenia are likely associated with excessive dopaminergic activity of the mesolimbic pathway,24 therefore, D2
blockade in this region would result in reduction in positive symptoms. Imaging studies have found a threshold
relationship between D2 receptor occupancy and antipsychotic drug efficacy.28 However, excessive D2 blockade also leads to EPS such as parkinsonism, dyskinesia,
akathisia, dystonia, and other motor side effects.28,29 In
the present study, C/C homozygotes experienced greater
positive symptom efficacy and greater akathisia, consistent with a hypothesis that the C (risk) allele allows for
greater sensitivity to D2 blockade. In vitro studies, as
well as neurochemical imaging in vivo studies, would be
required to directly test this hypothesis.
Previous studies have found that rs1799732 (−141C
Ins/Del), a SNP in the DRD2 promoter region, is associated with antipsychotic efficacy7,8 and drug-induced
weight gain.30 Another SNP nearby, rs1799978 (A-241G),
was also associated with antipsychotic drug response in a
first-episode schizophrenia cohort.7 Both SNPs are carried along the same haplotype with rs2514218 (D’ = 0.93
and 0.99, respectively, in the current dataset), although
allele frequencies differ and the overall correlation is low.
Still, it is plausible that rs2514218 is tagging the effects of
other DRD2 variants in antipsychotic response.
The present study utilized a cohort of patients with
first-episode psychosis to study pharmacogenetic markers of drug response. There are many advantages of
studying pharmacogenetics in this type of patients,
including minimal prior exposure to antipsychotic
drugs, less comorbidity and substance abuse, less confounding effects from other psychotropic drugs, and
better treatment adherence.31 Nevertheless, there are
limitations of the study. The sample size was small,
especially for subgroup analysis, so we may not have the
statistical power to detect significant genotype-phenotype associations, and findings may be less reliable (due
to a greater degree of error variance). Importantly, the
2 drugs used in the clinical trial might have somewhat
different mechanisms of action. Aripiprazole is a D2
partial agonist, aiming at normalizing dopaminergic
imbalance in schizophrenia and may act as an agonist
or antagonist at the D2 receptor, depending on synaptic
dopamine levels.32 In contrast, risperidone is more like a
typical antipsychotic drug with strong D2 antagonism.
These differences in pharmacodynamic processes may
contribute noise to a pharmacogenetic study of DRD2.
Furthermore, there were potential racial differences
between the 2 genotype groups that may influence the
findings. There were more African Americans in the C/C
group and more Caucasians in the T carriers. Although
the difference did not reach statistical significance,
P = .064, it is certainly a legitimate concern that racial
differences might influence the findings. Therefore, we
examined the difference in positive symptom response
1254

rates (as defined by 50%, 40%, 30%, and 20% reduction from baseline) and akathisia between African
Americans and Caucasians. For response rates, P values for race were all greater than .10. For akathisia,
results for race went in the opposite direction and, if
anything, weakened the relationship with genotype. In
addition, we utilized the genomic principal components
to control for potential racial differences and population stratification. Nevertheless, these findings need
to be replicated in larger and independent samples to
ensure their validity.
In summary, rs2514218, the top SNP from a replicable
schizophrenia risk locus, was associated with antipsychotic drug response. These findings provided further evidence to support the important role that DRD2 plays in
both schizophrenia risk and antipsychotic drug response.
Future studies should examine the pathophysiological
mechanisms of DRD2 genetic variation in schizophrenia
etiology and treatment.
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